
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides mutual fund investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. The company was incorporated in 2002 and is headquartered in Draper, Utah.
HealthEquity, Inc. trades as HQY on NASDAQ. The company is classified in Healthcare / Medical - Healthcare Information Services and reports in USD.
The current profile places the business in Medical - Healthcare Information Services. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.
Latest available fiscal data shows $1.31B of revenue and $215.20M of net income.
Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.
The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.
HealthEquity, Inc. can be compared against peers such as Bio-Rad Laboratories, Inc., BrightSpring Health Services, Inc. Common Stock, Corcept Therapeutics Incorporated, DaVita Inc., Globus Medical, Inc., Hims & Hers Health, Inc..
A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.
Current signals to investigate include market capitalization of $7.41B, beta of 0.21, and return on equity of +10.2%.
This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.
Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.
HQY currently shows total debt of $1.00B and beta of 0.21. Missing data should be treated as a research gap, not as low risk.
Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.
No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.
Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.
Recent filings to review: 4 (2026-06-02 00:00:00), 4 (2026-06-01 00:00:00), 4 (2026-06-01 00:00:00), 10-Q (2026-05-28 00:00:00).
Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.
Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.
Company website: https://www.healthequity.com
For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.